Objective. Osteoarthritis (OA) chondrocytes exhibit impairment of autophagy, one arm of the proteostasis network that coordinates proteome and organelle quality control and degradation. Deficient proteostasis impacts differentiation and viability, and inflammatory processes in aging and disease. The present study was undertaken to assess ubiquitin proteasome system proteasomal function in OA chondrocytes.
1
Objective. Osteoarthritis (OA) chondrocytes exhibit impairment of autophagy, one arm of the proteostasis network that coordinates proteome and organelle quality control and degradation. Deficient proteostasis impacts differentiation and viability, and inflammatory processes in aging and disease. The present study was undertaken to assess ubiquitin proteasome system proteasomal function in OA chondrocytes.
Methods. We evaluated human knee cartilage by immunohistochemistry, and assessed proteasomal function, levels of proteasomal core subunits and chaperones, and autophagy in cultured chondrocytes. Assays included Western blotting, quantitative reverse transcription-polymerase chain reaction, proteasomal protease activity assessment, and cell immunofluorescence analysis.
Results. Human knee OA cartilage exhibited polyubiquitin accumulation, with increased ubiquitin K48-linked polyubiquitinated proteins in situ, suggesting proteasomal impairment. Cultured OA chondrocytes demonstrated accumulation of K48 polyubiquitinated proteins, significantly reduced 20S proteasome core protease activity, and decreased levels of phosphorylated FOXO4 and proteasome 26S subunit, non-ATPase 11 (PSMD11), a FOXO4-inducible promoter of proteasomal activation. Levels of proteasome subunit b type 3 (PSMB3), PSMB5, PSMB6, and proteasome assembly chaperone 1 were not decreased in OA chondrocytes. In normal chondrocytes, PSMD11 small interfering RNA knockdown stimulated certain autophagy machinery elements, increased extracellular nitric oxide (NO) levels, and reduced chondrocytic master transcription factor SOX9 protein and messenger RNA (mRNA) and aggrecan (AGC1) mRNA. PSMD11 gain-offunction by transfection increased proteasomal function, increased levels of SOX9-induced AGC1 mRNA, stimulated elements of the autophagic machinery, and inhibited extracellular levels of interleukin-1-induced NO and matrix metalloproteinase 13 in OA chondrocytes.
Conclusion. Deficient PSMD11, associated with reduced phosphorylated FOXO4, promotes impaired proteasomal function in OA chondrocytes, dysregulation of chondrocytic homeostasis, and decreased levels of SOX9 mRNA, SOX9 protein, and AGC1 mRNA. Chondrocyte proteasomal impairment may be a therapeutic target for OA.
Osteoarthritis (OA) is a highly prevalent disease of the whole joint, in which aging, biomechanical injury, inflammation, metabolism, and other processes converge to promote altered articular chondrocyte differentiation and function, and ultimate cartilage failure (1) . Multiple hallmarks of tissue aging (2) are detected in OA articular chondrocytes (1) . These include deficient activities of cell homeostasis signaling by FOXO transcription factor and AMP-activated protein kinase (AMPK) (3, 4) , mitochondrial dysfunction (5, 6) , and dysregulated proteostasis (5, (7) (8) (9) (10) (11) .
The proteostasis network, which includes the unfolded protein response (UPR), autophagy, and the ubiquitin-proteasome system (UPS), coordinates proteome synthesis and folding, and uses chaperones to direct proteins to loci for degradation (12) (13) (14) . UPR activation alleviates stress from accumulation of damaged proteins in the endoplasmic reticulum lumen, but in some conditions, including experimental OA, dysregulated UPR activity can contribute to inflammation, tissue damage, and degeneration (14) (15) (16) . Conversely, distinct UPR genes and responses appear decreased in OA chondrocytes (17) .
The autophagic process primarily degrades proteins and organelles under hypoxic and low nutrition/energy states, thereby exerting quality control and generating cell energy via recycling (5, (7) (8) (9) (10) (11) . Autophagy is constitutively active in normal articular chondrocytes, promoted by factors including FOXO, AMPK, and regulated in development and DNA damage response 1 (REDD-1) (18) (19) (20) . Autophagy, AMPK activity, FOXO, and REDD-1 are decreased in aged and OA cartilage (3, 4, 19, 20) . Pharmacologic and transgenic inhibition of autophagy potentiates OA in mice (7, 8) , contrasting with the chondroprotective effects of autophagy up-regulation (7, 10, 11) .
The UPS accounts for~80-90% of cell protein breakdown in proteostasis, via preferential degradation, within proteasomes, of damaged polyubiquitinated proteins and many short-lived, regulatory cytosolic proteins (e.g., IjB, cyclins) (12, 21) . In the UPS, isopeptide bonds between ubiquitin and protein substrates are formed by ubiquitinactivating, ubiquitin-conjugating, and ubiquitin-protein ligases (E1, E2, and E3, respectively) (21) . Other ubiquitin molecules are sequentially conjugated to 1 of 7 lysine residues of attached ubiquitin, most commonly at ubiquitin K48, which targets proteins for proteasomal degradation (21) . Alternatively, mono-or polyubiquitination (e.g., via K63) affects protein function and trafficking and reduces pressure on the proteasome by stimulating substrate aggregation and removal by chaperone-mediated autophagy (21) (22) (23) (24) (25) .
The 26S proteasome, composed of 33 distinct subunits, is a cytosolic, energy-requiring ATP-driven "latent proteolytic machine" regulated largely via substrate access, subunit expression, assembly, turnover, and function (12, 21) . Polyubiquitinated proteins bind a multi-unit 19S "regulatory cap." Substrates are partially unfolded, facilitated by deubiquitinating enzymes, to enter the barrel-shaped 20S proteolytic core (12, 21) . The 20S particle has 4 heptameric rings; the 2 outer ring a-subunits regulate substrate access to the proteolytic core, and 2 inner ring b-subunits exert chymotrypsin-, trypsin-, and caspase-like activities (21) . The 19S cap ATPases stimulate proteolytic activity by opening the 20S "gate" for substrate access (21) . Additional regulation is exerted by proteasome-dedicated chaperones and subunits, including proteasome assembly chaperone 1 (PSMG1) (26) and proteasome 26S subunit, non-ATPase 11 (PSMD11) (27) (28) (29) (30) . The UPS also networks extensively with autophagy (12,13), FOXOs, and AMPK (31, 32) .
Differing proteostasis demands, aging patterns, and stressors are linked with variances in UPS composition and activity between tissues, and with age (33) . Robust UPS capacity in youth maintains proteome integrity and inhibits senescence (34) . Aging facilitates UPS failure via accumulated misfolded proteins, and in some tissues, UPS collapse under stress predates aging (21) . UPS failure promotes multiple hallmarks of aging (12, 13, 21, 22, 31) , senescence and death in cells, disease in multiple tissues, and decreased organism longevity (21) .
Prior studies using modulation of proteasomal function in OA have been limited to experimental rat and mouse knee OA in young, wild-type animals (35) (36) (37) (38) . Those investigations assessed nascent disease triggered by surgically induced knee instability or monosodium iodoacetate, and principally analyzed effects of potent, broad proteasomal protease pharmacologic inhibition using the peptide aldehyde MG132, with administration started prior to OA onset (35) (36) (37) (38) . MG132 treatment was chondroprotective, with the integrity of proteasomal function appearing to be permissive for OA development and early disease advancement; decreased proteasomal degradation of the NF-jB inhibitor IjB was implicated in these effects, by lessening inflammation and cartilage matrix catabolism (35) (36) (37) (38) . In the present study, we characterized proteasomal dysfunction in human chondrocytes from human donors with knee OA. The results elucidated previously unidentified potential pathophysiologic impacts of chondrocyte proteasomal impairment in established human OA, and a molecular mechanism for selective reversibility of some OA-promoting effects in diseased chondrocytes via improved proteasomal function.
MATERIALS AND METHODS
Reagents. Except as otherwise noted, all chemical reagents were from Sigma-Aldrich. Recombinant human interlukin-1b (IL-1b) was from Gemini Bio-Products. High-glucose Dulbecco's modified Eagle's medium (DMEM) with L-glutamine and penicillin/streptomycin solution was from Mediatech. The matrix metalloproteinase 13 (MMP-13) enzyme-linked immunosorbent assay kit was from ThermoFisher.
Human tissue samples and cell culture. All human subject studies were approved by the San Diego Veterans Administration and Scripps Research Institute Institutional Review Boards. Human knee chondrocytes were isolated from autopsy donors and were graded macroscopically, as previously described (6) . We studied samples graded 0 (normal), I (cartilage with an intact surface), and IV (moderate-to-severe OA, with overt fibrillation). There was no preselection of donors or donor samples for any characteristic other than OA or non-OA. Chondrocytes were cultured in high-glucose DMEM with L-glutamine and 100 IU/ml penicillin/100 lg/ml streptomycin, supplemented with 10% fetal calf serum, at 37°C (6). Chondrocytes were studied at first passage or, where indicated, as primary cells.
Immunohistochemistry analysis. Paraffin-embedded human knee cartilage sections were incubated with primary antibody for 18 hours at 4°C. We used rabbit anti-K48-linked proteins (05-1307; EMD Millipore) and anti-total ubiquitin (sc-166553; Santa Cruz Biotechnology) antibodies. With horseradish peroxidase (HRP)-conjugated secondary antibodies we used a SuperPicture Polymer Detection Kit (Thermo Scientific), with diaminobenzidine substrate for colorimetric detection.
Transfection and expression plasmid construction. Human PSMD11 complementary DNA (cDNA) (pQTEV-PSMD11, ID 31333; Addgene) was amplified by polymerase chain reaction (PCR) and subcloned, with and without human influenza hemagglutinin (HA) tagging at the N-terminal, into pCDNA3.1+ plasmid vector between the Xho I and Bam HI sites, with verification by sequencing. Primers are listed in Supplementary Western blotting. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of cultured chondrocyte lysates in Bis-Tris gels (Thermo Scientific) and Western blotting were performed as previously described (6) . Primary antibodies to PSMG1 (#13378), PSMD11 (#14303), proteasome subunit b type 5 (PSMB5) (#12919), PSMB6 (#13267), caspase 3 (#9662), poly (ADP-ribose) polymerase (#9532), FOXO1 (#2880), FOXO3a (#12829), FOXO4 (#2499), phosphorylated FOXO1/FOXO3a (#9464), SOX9 (#82630), light chain 3A/B (LC3/A/B; #12741), p62 (#8025), and HA-tag (#3724) were from Cell Signaling Technology. Antibodies to phosphorylated FOXO4 (#47278) and to MMP-13 (#3533) were from Abcam and BioVision, respectively, and antibody to PSMB3 (#140458) was from Abcam. Secondary antibodies (1:5,000) were conjugated with HRP and detected with ECL reagent (Super Pico or Femto; Thermo Scientific), using either x-ray film or a Gel Doc system (Bio-Rad). Quantification of band intensity was performed with ImageStudioLite (Li-Cor), with intensity of bands calculated relative to the background from the same membrane.
Proteasome activity assay. Proteasome activity assays were performed to analyze chymotrypsin-like activity at the core proteasome particle, utilizing an AMC-tagged peptide substrate (Succ-LLVY-AMC) that releases free, highly fluorescent AMC in the presence of protease activity. Briefly, cells were lysed at 4°C in phosphate buffered saline (PBS) containing 0.5% Nonidet P40, followed by centrifugation (15,000 revolutions per minute, 4°C). After determination of protein levels, the supernatant was assayed for chymotrypsin-like activity using a proteasome activity kit (ab107921) according to the instructions of the manufacturer (Abcam). Aliquots of protein (10 lg), including samples and positive control from the manufacturer, were assayed in triplicate, with and without proteasome inhibitor MG132 (200 lM) and incubated in the dark for 30 minutes at 37°C. Output at 350/440 nm (excitation/emission) was measured on a fluorometric microplate reader at time 1 (T1) and time 2 (T2; 25 minutes later). Relative fluorescence units (RFU) were determined as follows:
where iRFU represents wells containing proteasome inhibitor showing nonproteasome activity. Proteasome activity was calculated as
where B = amount of AMC in the sample well (pmoles), V = sample volume (ll) added to the reaction well, T1 = time (minutes) of the first reading (RFU T1 and iRFU T1 ), T2 = time (minutes) of the second reading (RFU T2 and iRFU T2 ), and D = sample dilution factor. Calibration curves were calculated for AMC concentration and purified 20S proteasome activity.
Quantitative reverse transcription-PCR (RT-PCR).
RNA was extracted and isolated from cultured human chondrocytes utilizing an RNeasy Mini kit (Qiagen). RNA levels were quantified with a NanoDrop 1000 spectrophotometer (Thermo Scientific); samples with 260 nm/280 nm absorbance ratios of >2.0 were used for RT. Equal amounts of total RNA from each sample were subjected to RT-PCR using a Transcriptor High Fidelity cDNA Synthesis Kit (Roche), which includes anchored oligo(dT) 18 and random hexamer primers. Quantitative RT-PCR was performed using a 480 Light Cycler (Roche) and specific primer sets (Supplementary Table 1 , http://onlinelibrary.wiley.com/doi/10.1002/art.40456/abstract). Levels of messenger RNA (mRNA) for genes of interest were calculated as fold change from control or as the ratio of the copy number of the gene of interest to the copy number of the total housekeeping gene GAPDH. For absolute quantification, a pGEM-T Easy vector system (Promega) was used to clone gene fragments (GAPDH, AGC1, SOX9, and PSMD11).
Immunofluorescence analysis. Human chondrocytes were cultured for 16-18 hours on 6-well plates containing round coverslips (12 mm; VWR) and then transfected for 72 hours (XtremeGENE siRNA Transfection Reagent; Roche) with PSMD11 small interfering RNA (siRNA) (On-Target, L-011367-01-0005; GE Dharmacon). Culture medium was removed from plates, and cells were fixed/permeabilized with cold methanol (À20°C) for 15 minutes. Serial washes were performed with PBS, followed by blocking with 1% bovine serum albumin in PBS for 2 hours at room temperature. Incubation with primary IgG was conducted overnight at 4°C with rabbit anti-LC3A/B, rabbit anti-lysosome-associated membrane protein 1 (ab24170; Abcam), or rabbit anti-p62/sequestosome 1 (88588; Cell Signaling Technology). Incubation with secondary antibodies was done for 2 hours at 22°C, using Alexa Fluor 488-conjugated goat antirabbit IgG (A11034; Thermo Fisher) or Alexa Fluor 555-conjugated goat anti-rabbit IgG (21429; Thermo Scientific). A BZ-X700 microscope (Keyence) was used for imaging.
Chromatin immunoprecipitation (ChIP) assay. We tested a defined, specific 48-bp sequence in the SOX9-binding enhancer region of the type II collagen a1 chain (COL2A1) for cartilage expression (39) . We also assessed a defined, functional SOX9-hypoxia-inducible factor 1a complex binding site in the 5 0 -untranslated region (5 0 -UTR) of AGC1 (40) . To do so, we used primers corresponding to nucleotides 60-82 (forward) and 220-240 (reverse) in the AGC1 À640 to À510 5 0 -UTR (GenBank accession no. AF031586). ChIP assay was performed according to the instructions of the manufacturer (Millipore), using protein A-agarose/salmon sperm DNA (50% slurry) to reduce nonspecific background, and immunoprecipitation with SOX9 antibody (ab3697; Abcam). Following elution of histone-DNA complexes and DNA recovery by phenol/chloroform extraction, DNA was resuspended in 10 ll TE buffer. PCR was conducted with 1 ll eluate, 2 ll of 20 lM primers for COL2A1 and AGC1 (Supplementary Table 1 Statistical analysis. GraphPad Prism was used for statistical analysis. The significance of differences between mean values from unpaired samples was assessed by two-way analysis of variance with Bonferroni post hoc test or by unpaired t-test.
RESULTS
Increased levels of ubiquitinated protein substrates in human OA chondrocytes and OA cartilage in situ. We observed increased levels of ubiquitinated proteins in OA chondrocytes compared to normal chondrocytes, on Western 1032 SERRANO ET AL blots of cell lysates analyzed for total ubiquitin ( Figure 1A ) and K48-linked substrates ( Figure 1B) . Levels of both ubiquitin ( Figure 2A ) and K48-linked polyubiquitin ( Figure 2B ) were also increased in human knee OA cartilage compared to normal cartilage, as assessed by immunohistochemistry. In grade IV OA cartilage specimens, polyubiquitin staining was particularly intense in chondrocyte clusters ( Figure 2B ). Decreased chondrocyte proteasome activity in OA. Proteasome activity was significantly decreased in cultured chondrocyte lysates from grade IV OA samples compared to samples from normal donors ( Figure 3A) . Western blot examination of 3 of the 7 20S proteasome core b-subunit constituents of the inner ring, where catalytic activity is localized, revealed no significant decrease in PSMB3, PSMB5, or PSMB6 levels in grade IV OA chondrocytes ( Figure 3B ). Hence, we assessed the critical proteasome regulatory subunits PSMG1 and PSMD11 (27, 28) , since PSMG1 facilitates 20S proteasome assembly by promoting grouping of the b-subunits into the heteroheptameric a ring (26) and PSMD11 stabilizes the interaction between the Figure 1 . Increased levels of ubiquitin and polyubiquitinated substrates in human knee osteoarthritis (OA) chondrocytes. Equal aliquots (10 lg) of lysates from normal (grade 0/grade I) and grade IV OA human articular chondrocytes were used for sodium dodecyl sulfate-polyacrylamide gel electrophoresis/Western blot analysis, utilizing antibodies directed against ubiquitin (n = 8 per group) (A) and K48-linked ubiquitin (n = 9 per group) (B). Equal protein loading was confirmed by blotting for b-actin.
19S and 20S subunits of the proteasome (27, 28) . PSMG1 levels were not significantly decreased in OA chondrocytes ( Figure 3C ). In contrast, however, OA chondrocytes exhibited decreased levels of PSDM11 protein ( Figure 4A ) and mRNA ( Figure 4B ). Levels of FOXO4, a transcription factor that stimulates PSMD11 mRNA expression (28, 31) , were comparable in normal and OA chondrocytes. Phosphorylation of FOXOs is required for translocation to the nucleus and subsequent functionality (41), and we observed markedly reduced levels of p-FOXO4 in OA chondrocytes compared to normal chondrocytes ( Figure 4C ).
Decreased PSMD11 reduces levels of SOX9 and AGC1 mRNA in chondrocytes. We first assessed, via transfection with PSMD11 siRNA, the functional implications of selective decrease of PSMD11 expression in normal chondrocytes. We validated induction of decreases in levels of PSMD11, associated with reduced proteasome activity and increased levels of K48 polyubiquitinated peptides (Supplementary Figures 1A and B Figure 1C) . Under these conditions, in normal chondrocytes, PSMD11 knockdown induced a >70% increase in extracellular NO levels in response to IL-1b (10 ng/ml), but there was no significant difference in MMP-13 protein levels ( Figure 5A ). MMP3 and MMP13 mRNA levels were not significantly affected by PSMD11 siRNA (results not shown). In contrast, PSMD11 siRNA knockdown reduced SOX9 and AGC1 mRNA levels ( Figure 5B ) and attenuated SOX9 protein in normal chondrocytes ( Figure 5C ). In normal chondrocytes, PSMD11 siRNA stimulated multiple elements of the autophagic machinery, specifically evidenced by LC3A/B-I to LC3A/B-II conversion and increased levels of the autophagy-UPS adaptor and LC3-binding protein p62 (13) (Figure 5C ), with associated perinuclear colocalization of p62 and LC3A/B ( Figure 5D ). Effects of PSMD11 gain-of-function in human OA chondrocytes. Since levels of PSMD11 were decreased in grade IV OA chondrocytes, we induced selective PSMD11 gain-of-function by transfection in OA cells. To do so, we used an approach previously shown to be effective in stem cells (28) . Transfecting HA-tagged PSMD11 cDNA, we achieved significant increases in proteasome activity and observed associated decreases in levels of K48 polyubiquitinated substrates in OA chondrocytes (Figures 6A and B) , markedly lower levels of IL-1b-induced extracellular NO (Supplementary Figure 2A, Supplementary Figures 2A  and B) , and increased SOX9 protein in 5 of 5 human OA chondrocyte donor samples tested ( Figure 6C ). Moreover, Figure 3 . Proteasome activity is diminished in osteoarthritis (OA) chondrocytes, without significant decreases in levels of critical 20S inner ring bsubunits (proteasome subunit b type 3 [PSMB3], PSMB5, PSMB6) and proteasome assembly chaperone 1 (PSMG1). A, Lysates were collected from normal chondrocytes (n = 8) and grade IV OA chondrocytes (n = 8) in the absence of protease inhibitors, and protein aliquots (10 lg) were assayed for 20S proteasome function using Succ-LLVY-AMC substrate (37°C, excitation/emission 350 nm/440 nm). Replicate controls were assayed with proteasome inhibitor MG132 (200 lM). We observed a >50% decrease in proteasome protease activity in OA chondrocytes. Symbols represent individual donors; bars show the mean AE SEM. **** = P < 0.0001 by unpaired t-test. B and C, Aliquots (10 lg) of protein extracted from primary chondrocytes (n = 9 normal; n = 9 grade IV OA) were analyzed by Western blotting to determine levels of critical 20S proteasomal inner ring b-subunits, revealing that there was no significant variation between normal and grade IV OA samples (B) and that levels of PSMG1 were not appreciably decreased in OA chondrocytes compared to normal donor cells (C).
ChIP assays demonstrated that PSMD11 gain-of-function increased SOX9 binding to the AGC1 5 0 -UTR and COL2A1 enhancer ( Figure 6D ). Under these conditions, PSMD11 gain-of-function stimulated multiple elements of the autophagic machinery, evidenced by changes in LC3A/B conversion and p62 (Supplementary Figure 3A, http://onlinelibrary. wiley.com/doi/10.1002/art.40456/abstract) and associated increases in perinuclear colocalization of p62 and LC3A/B in 5 of 5 OA chondrocyte donor samples tested (data not shown). Last, PSMD11 transfection induced increased SOX9 nuclear localization and levels of SOX9, AGC1, and COL2A1 mRNA in OA chondrocytes ( Supplementary Figures 3B and C) .
DISCUSSION
In this study, we demonstrated that proteasomal function is impaired in human knee OA chondrocytes, and that integrity of proteasomal function plays a significant role in maintenance of differentiation of cultured chondrocytes. Our studies included analyses of intersections between proteasomal function and autophagy in normal and OA chondrocytes.
Selective induction of proteasomal dysfunction in normal donor chondrocytes, achieved using PSMD11 siRNA, stimulated multiple elements of the autophagic machinery, including p62 and p62 perinuclear colocalization with LC3. This finding may be due to an acute stress A, Western blotting of chondrocyte lysates, with densitometric analysis, revealed decreased PSMD11 levels in grade IV OA compared to normal donor cells. B, Analysis by reverse transcriptase-polymerase chain reaction demonstrated that PSMD11 mRNA levels were significantly decreased in grade IV OA compared to normal chondrocytes. Western blotting with densitometric analysis also revealed decreased p-FOXO4 levels, but no consistent changes in levels of total FOXO4, in grade IV OA compared to normal donor chondrocytes. Symbols represent individual donors; bars show the mean AE SEM. ** = P = 0.0013; *** = P = 0.0008; **** = P < 0.0001, by unpaired t-test.
response to PSMD11 knockdown in healthy cells able to adaptively increase autophagy to support proteostasis. Gain of proteasomal function in OA donor chondrocytes, achieved selectively by PSMD11 transfection, induced increases in elements of the autophagic machinery. Distinct autophagic pathways (microautophagy, chaperone-mediated autophagy, and macroautophagy) effect degradation of cytosolic proteins, using multiple enzymes and differing cargo delivery to lysosomes or vacuoles, and with ordered phases of each process (13) . Full examination of cross-talk between the UPS and autophagy processes (13) , and evaluation of ultimate autophagic protein degradation, were beyond the scope of this study. However, effectiveness of the autophagic process in OA chondrocytes is known to be Figure 5 . PSMD11 small interfering RNA (siRNA) knockdown induces increased extracellular nitric oxide (NO) levels, decreased SOX9 levels, and diminished AGC1 mRNA levels and stimulates elements of the autophagy process in normal chondrocytes. We studied the effects of PSMD11 siRNA knockdown on extracellular NO and matrix metalloproteinase 13 (MMP-13) levels in response to interleukin-1b (IL-1b) treatment (10 ng/ml) in normal human knee chondrocytes (A). We also analyzed the effects of PSMD11 siRNA on AGC1 and SOX9 mRNA (B), on SOX9, on autophagyrelated light chain 3A/B-I (LC3A/B-I) to LC3A/B-II conversion, and on the autophagy-ubiquitin-proteasome system adaptor and LC3-binding protein p62 (C), and on perinuclear colocalization of p62 and LC3A/B-I to LC3A/B-II conversion in normal chondrocytes (D) (original magnification 9 40), with 300 cells per treatment counted to quantify structures where LC3A/B and p62 colocalized. P values were determined by two-way analysis of variance (multiple comparison with Bonferroni post hoc test). In A, B, and D, bars show the mean AE SEM. * = P = 0.037; *** = P = 0.0004. RQ = relative quantity. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.40456/abstract. decreased once OA is well-established (3, 4, 19, 20) . As such, our results suggest that compromise of proteasomal function is likely more deleterious in aging and OA chondrocytes (12) by a compound proteostasis defect that includes autophagy impairment (7) (8) (9) (10) (11) . The impact of proteasomal dysfunction in OA chondrocytes could potentially be amplified by decreased autophagic removal of damaged proteasomes (42) .
Our study defined molecular mechanistic factors contributing to deficient proteasomal function in human knee OA chondrocytes, and associated accumulation of K48 polyubiquitinated substrates. Specifically, we linked proteasomal dysfunction in OA chondrocytes to decreases in PSMD11 and the PSMD11 transcription inducer p-FOXO4, but not total FOXO4. PSMD11, a 19S proteasomal subunit, is required for assembly of a functional 20S proteasomal core (27, 28, 31) . Essentially, 20S particles exist as free complexes, with constitutively latent proteolytic activity primed by 19S particle ATPases that also permit access of proteins to the 20S core (27, 28) . Two members of the FOXO family, FOXO1 and FOXO3, are decreased in aging and OA chondrocytes in vitro, and Figure 6 . Effects of selective proteasome 26S subunit, non-ATPase 11 (PSMD11) gain-of-function in cultured human knee osteoarthritis (OA) chondrocytes. A and B, Transfecting grade IV OA chondrocytes, we assessed the effects of hemagglutinin (HA) tag-PSMD11 plasmid, compared to control plasmid transfection, on proteasome activity (A) (n = 5 normal donors; n = 5 OA donors) and on accumulation of K48-polyubiquitinated proteins (B). In A, symbols represent individual donors; bars show the mean AE SEM. *** = P = 0.0003 by unpaired t-test. In B, representative results are shown. C, Effects of PSMD11 gain-of-function, by transfection in OA chondrocytes (n = 5 different donors), on SOX9 levels were assessed, and its ability to augment cellular HA was validated. D, By chromatin immunoprecipitation assay, we separately analyzed the effect of PSMD11 gain-of-function on nuclear SOX9 binding to the AGC1 5 0 -untranslated region and to COL2A1 enhancer.
1038 SERRANO ET AL articular cartilage in situ (3, 19) . Though FOXO1 and FOXO3 are far more abundant than FOXO4 in human articular chondrocytes, unlike FOXO4 they do not have a defined role in regulating proteasomal activity. The observed decrease in PSMD11 in OA chondrocytes was at least partially selective, relative to other modulators of proteasome assembly and 20S proteasomal core protease activity. Specifically, 3 inner ring b-subunits and the 20S particle assembly chaperone PSMG1 were not decreased in OA compared to normal human knee chondrocytes. Another central finding was that selective PSMD11 gain-of-function by transfection improved proteasomal function in OA chondrocytes, evidenced by increased 20S chymotrypsin-like proteolytic activity and decreased K48 polyubiquitinated substrates. PSMD11 is regulated by factors other than FOXO4, including cAMP and protein kinase A (PKA) signaling, which transcriptionally support PSMD11 expression (30) . However, cAMP and PKA signaling have mixed effects on matrix catabolism by articular chondrocytes that would theoretically limit their potential translational utility in increasing proteasomal function in OA chondrocytes.
Selective modulation of PSMD11, beyond effects on proteasomal function, had marked functional impact in normal and OA chondrocytes, with major effects on maintenance of SOX9 and chondrocytic differentiation. We identified affected responses to include levels of SOX9 protein and SOX9 nuclear translocation and binding to regions in the AGC1 5 0 -UTR and COL2A1 enhancer, and levels of AGC1 and COL2A1 mRNA expression. SOX9 is influenced by multiple signals, including those provided by a variety of growth factors, transcription factors, and epigenetic modifications (43) . As such, the net contributions of PSMD11 and proteasomal function on SOX9, AGC1, and maintenance of articular chondrocytic differentiation, remain to be determined in both early and late OA.
PSMD11-selective modulation of proteasomal function significantly affected IL-1b-triggered extracellular NO levels in both normal and OA chondrocytes, and extracellular MMP-13 in OA chondrocytes. The NO findings carry significance partly due to the capacity of NO to exert both antianabolic and procatabolic effects on extracellular matrix homeostasis in cartilage, including suppression of proteoglycans and collagen synthesis (44) . Additionally, excess NO promotes chondrocyte apoptosis (45, 46) . NO is generated and degraded by a variety of mechanisms in chondrocytes (46) . Moreover, the UPS regulates NO metabolism by complex and paradoxical mechanisms, including regulation of inducible NO synthase (iNOS) expression by NFjB, and of proteasomal degradation of iNOS (47, 48) . Hence, the mechanism of the observed capacity of proteasomal dysfunction to modulate extracellular NO in chondrocytes could be multifactorial.
Both UPS dysfunction and OA increase progressively with aging (1, 2, 21) , and this study was not designed or powered to distinguish effects of aging from those of OA in chondrocytes. That question clearly will require further study. Another limitation is that our studies of protease activity in isolated proteasomes from cytosol, rather than whole cells, could have readily underestimated the extent of decreased proteasomal function in OA chondrocytes. In this context, substrate selection and gate opening are highly regulated processes that are highly dependent on ATP. OA chondrocytes have decreased ATP levels, largely due to mitochondrial dysfunction (6) .
Our results support a model in which impaired chondrocyte proteasomal function in established OA renders cartilage damage more difficult to slow and potentially reverse. However, there could well be substantially less chondrocyte proteasomal impairment in earlier stages of OA, such as those previously studied (35) (36) (37) (38) . The chondrocyte UPS dysfunction studied here may reflect an advanced stage of disease, given that we focused on chondrocytes from donors with advanced (grade IV) OA. Further studies on UPS effects in chondrocytes from early OA cartilage would be of interest. In this regard, multiple pharmacologic proteasome protease inhibitors, including MG132, increase autophagy in normal cells (13, 49) . As such, our results suggest that chondroprotective effects of MG132 administration in young rodents with nascent experimental knee OA (35) (36) (37) (38) may have been partly mediated by induction of increased autophagy in the normal chondrocytes of these young animals. Other in vivo chondroprotective mechanisms of pharmacologic proteasomal inhibition by MG132 in young animals could include suppression of articular inflammatory processes, cartilage matrix catabolism, and pain (35) (36) (37) (38) , partially via increased protein stability of the proteasomal degradation-regulated native NF-jB inhibitor IjB (37, 38) .
Proteasomal protease inhibitors such as MG132 are only one means to elucidate proteasome function in OA. Specifically, in a study of rodent knee instability-induced OA using mice transgenic for K48R-mutated ubiquitin to investigate focused interference with polyubiquitination, only marginal and focal chondroprotection was observed, albeit in a system with potentially problematic residual effects of endogenous normal ubiquitin (38) . Ultimately, investigations into the impact of the phenotype of proteasomal dysfunction in OA chondrocytes would benefit most from replication of specific molecular mechanisms that cause impairment of proteasomal function. This is particularly the case because not only proteasomal core proteases, but also deubiquitinases, impart and tune proteasomal functionality (13, 21) .
In conclusion, we have provided what is, to our knowledge, the first evidence of impaired proteasomal function in human OA chondrocytes. We mechanistically linked decreases in chondrocyte PSMD11 and p-FOXO4 to consequent decreases in SOX9, and in AGC1 and COL2A1 mRNA levels, along with increased extracellular NO in response to inflammatory stimulation. However, we note that UPS dysfunction promotes disease partly by effects on diverse processes, promoting mitochondrial dysfunction, oxidative stress, and altered insulin-like growth factor receptor, insulin receptor, phosphatidylinositol 3-kinase, and Akt signaling (12, 13, 21, 22, 31) . Translationally, our results revealed that proteasomal gain-of-function, achieved in a highly selective manner by PSMD11 gain-of-function, stimulated elements of the autophagy process in both normal and advanced knee OA chondrocytes, and also increased SOX9, AGC1 5 0 -UTR, and COL2A1 enhancer binding, and AGC1 and COL2A1 mRNA levels. There are emerging pharmacologic means to up-regulate 20S proteasomal activity, including by use of small molecules such as deubiquitinase inhibitors (50) . The chondrocyte proteasome could provide a novel, pharmacologically targetable therapy in OA, which would potentially be more chondroprotective in well-established disease.
